<DOC>
	<DOCNO>NCT03058783</DOCNO>
	<brief_summary>Efficacy Safety IDP-124 Lotion Treatment Moderate Severe Atopic Dermatitis Pediatric Adult Subjects</brief_summary>
	<brief_title>Efficacy Safety IDP-124 Lotion Treatment Moderate Severe Atopic Dermatitis Pediatric Adult Subjects</brief_title>
	<detailed_description>A Multicenter , Randomized , Double-Blind , Vehicle-Controlled , Study Evaluate Efficacy Safety IDP-124 Lotion Treatment Moderate Severe Atopic Dermatitis Pediatric Adult Subjects</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Male female least 2 year age old Written verbal informed consent must obtain ; subject less age consent must sign assent study parent legal guardian must sign informed consent ( subject reach age consent study reconsented next study visit ) Nonimmunocompromized male female fail respond adequately topical prescription treatment AD treatment advisable Subjects must willing comply study instruction return clinic require visit ; subject age consent must accompany parent legal guardian time assent/consent signing Females pregnant , breast feeding , wish become pregnant study period Active cutaneous bacterial viral infection treatment area Baseline ( eg , clinically infected AD ) Sunburn , extensive scarring , pigment lesion ( ) treatment area Baseline , would interfere evaluation History confound skin condition , eg , psoriasis , rosacea , erythroderma , ichthyosis ( ichthyosis vulgaris ) History presence : basal cell carcinoma skin effectively treat 2 year ago carcinoma cervix effectively treat 5 year ago immunological deficiency disease , HIV , serious recurrent infection clinically significant severe renal insufficiency severe hepatic disorder Current recent serious infection</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>